Description: IVERIC bio, Inc., formerly Ophthotech Corporation, is a biopharmaceutical company. The Company is focused on the discovering and developing of novel gene therapy solutions to treat orphan inherited retinal diseases, with a focus on diseases of the back of the eye. Its primary focus is developing therapeutics for age-related macular degeneration (AMD), which is a disorder of the central portion of the retina, known as the macula, that may result in blindness. The Company’s BEST1 gene encodes a multifunctional protein known as bestrophin1, that regulates ion transport and intracellular calcium signaling in retina cells and helps maintain homeostasis in the sub retinal space between photoreceptors and the retinal pigment epithelial (RPE) cells. Its IC-200 is a mutation independent gene therapy, delivered by an AAV2 vector.
Home Page: ivericbio.com
ISEE Technical Analysis
8 Sylvan Way
Parsippany,
NJ
07054
United States
Phone:
609 474 6755
Officers
| Name | Title |
|---|---|
| Mr. Glenn P. Sblendorio M.B.A. | CEO & Director |
| Dr. Pravin U. Dugel M.D. | Pres |
| Mr. David F. Carroll M.B.A. | Sr. VP, CFO & Treasurer |
| Mr. Christopher Paul Simms | Sr. VP & Chief Commercial Officer |
| Mr. Anthony S. Gibney | Exec. VP and Chief Bus. & Strategy Officer |
| Dr. Samir C. Patel | Co-Founder and Consultant |
| Mr. Keith Westby M.B.A. | Sr. VP & COO |
| Dr. Xiao-Ping Dai Ph.D. | Chief Technical Officer |
| Ms. Kathy Galante | Sr. VP of Investor Relations & Corp. Communications |
| Mr. Todd D.C. Anderman | Sr. VP, Gen. Counsel & Corp. Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.805 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2013-09-25 |
| Fiscal Year End: | December |
| Full Time Employees: | 148 |